Woodley Farra Manion Portfolio Management Inc. Sells 211,614 Shares of Johnson & Johnson $JNJ

Woodley Farra Manion Portfolio Management Inc. cut its holdings in Johnson & Johnson (NYSE:JNJ) by 96.6% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 7,544 shares of the company’s stock after selling 211,614 shares during the period. Woodley Farra Manion Portfolio Management Inc.’s holdings in Johnson & Johnson were worth $1,152,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Vanguard Group Inc. raised its position in Johnson & Johnson by 0.5% in the first quarter. Vanguard Group Inc. now owns 233,962,679 shares of the company’s stock valued at $38,800,371,000 after purchasing an additional 1,170,120 shares during the last quarter. Geode Capital Management LLC raised its position in Johnson & Johnson by 2.1% in the 2nd quarter. Geode Capital Management LLC now owns 60,609,476 shares of the company’s stock valued at $9,227,988,000 after buying an additional 1,225,676 shares during the last quarter. Northern Trust Corp increased its position in shares of Johnson & Johnson by 0.4% during the first quarter. Northern Trust Corp now owns 30,943,820 shares of the company’s stock valued at $5,131,723,000 after acquiring an additional 130,645 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Johnson & Johnson by 2.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 23,802,503 shares of the company’s stock worth $3,635,832,000 after purchasing an additional 620,039 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Johnson & Johnson by 3.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 18,899,263 shares of the company’s stock worth $3,133,602,000 after acquiring an additional 712,181 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

JNJ opened at $196.00 on Friday. The stock has a fifty day simple moving average of $185.81 and a two-hundred day simple moving average of $169.94. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $197.18. The company has a market cap of $472.22 billion, a price-to-earnings ratio of 18.92, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The business had revenue of $24.02 billion during the quarter. Research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Analysts Set New Price Targets

A number of brokerages recently issued reports on JNJ. Loop Capital set a $190.00 price objective on Johnson & Johnson in a research report on Wednesday, October 22nd. Bank of America upped their price objective on Johnson & Johnson from $198.00 to $204.00 and gave the stock a “neutral” rating in a report on Wednesday, October 15th. Morgan Stanley set a $190.00 target price on Johnson & Johnson in a research note on Wednesday, October 15th. HSBC lifted their price target on shares of Johnson & Johnson from $210.00 to $215.00 and gave the stock a “buy” rating in a research note on Thursday, October 16th. Finally, Wells Fargo & Company set a $212.00 target price on shares of Johnson & Johnson and gave the company an “overweight” rating in a report on Friday, October 3rd. Four equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $201.05.

Insider Activity

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.